Oxford BioDynamics Plc present strong data at ASH Summit

Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented:

“There have been many exciting breakthroughs in the immunotherapy of cancerous and non-cancerous hematologic diseases, including immune checkpoint inhibitors. However, questions of safety and efficacy present significant challenges, with a high demand for molecular biomarkers that may help to predict clinical outcomes.

Our aim is to develop and deliver non-invasive prognostic biomarkers in this fast developing and competitive field, and we were pleased to present strong data at this ASH Summit. Our EpiSwitch™ technology could stratify and predict which patients would not respond adequately to checkpoint inhibitor therapy, with high accuracy. We are very pleased with the interest our data have generated amongst the leaders in the field.

We believe that successful epigenetic stratifications of patients using EpiSwitch™ biomarkers could help improve understanding of the regulatory mechanisms in blood disorders, gain valuable insights into new targets and treatment designs, as well as help improve patients outcomes by supporting clinical decisions on the most appropriate and effective treatment option.”

Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has presented its latest EpiSwitch™ data in a plenary talk at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematologic Diseases, 12-13 July 2018, Washington DC, entitled: “Chromosome Conformation Monitoring for Prognostic Stratifications of Non-responders to Cancer Immunotherapies: Deconvolution of Epigenetic data with EpiSwitch™.”

Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, presented data on prognostic blood-based stratifications of patients with a common type of Non-Hodgkin lymphoma, and on predictive biomarkers for response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. Data presented from several indications successfully demonstrated that EpiSwitch™ epigenetic biomarkers identified in patients’ blood could help identify patients that will not respond adequately to anti-PD-1 or anti-PD-L1 monotherapy. Based on further analysis of more than 126 patients, this validation study demonstrated 94% accuracy in predicting response to the anti-PD-L1 treatment.

Immunotherapy, particularly immune checkpoint inhibitor PD-1/PD-L1 treatments, is a type of therapy that harnesses a person’s immune system to fight cancer cells. Lymphomas represent a broad range of blood cancers based on diseases of white cells. While Hodgkin lymphomas show good response to immunotherapies, response and efficacy in other lymphomas remain modest at best. OBD is actively involved in the fast moving field of immunotherapy, with a number of proprietary and commercial studies based on immune checkpoint inhibitors, monotherapies and combination therapies, for a growing list of cancer types.

Through the development of epigenetic biomarkers, OBD’s EpiSwitch™ technology can help pharmaceutical and biotechnology companies bring drugs to the market sooner through personalising drugs to patients most likely to respond, delivering better clinical outcomes.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA is often

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role in the proteasome,

    Oxford BioDynamics

    New questions about Covid-19

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more at risk,

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities such as

    Oxford BioDynamics

    ALS Awareness

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in response to

    Oxford BioDynamics

    ALS Awareness Month This May

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated the letters

    Oxford BioDynamics

    Microarray Facility

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of multiplex formats

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that integrate environmental

    No more posts to show